MedPath

Natural Microbiota Restoration After C-section Birth

Not Applicable
Completed
Conditions
Insufficient Intestinal Microbiota Diversity After C-section Birth
Interventions
Other: perineal impregnated swab
Other: clean swab
Registration Number
NCT02567071
Lead Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Brief Summary

The proportion of cesarean deliveries reached 30% of births in the US in 2008, while in the 1970s, it rarely reached 15%, as recommended by WHO. According to recent reports in some hospitals in China the use of cesarean section increased from 5% in the 1970s to over 60%. The use of C-section continues to grow in every countries of the world despite that current knowledge leads us to think that the vaginal birth, retained through millennia during mammalian evolution, guarantees the implementation of the best suited intestinal microbiota to build immunity and beneficial protective functions under the balanced mutual association between the host and its microbiota. Oral administration of a previously impregnated swab, by vaginal and maternal perineal secretions, following birth by planned C-section, would restore the normal development of the newborn intestinal microbiota mimicking exposure to these secretions during vaginal delivery.

The expected benefit is the establishment of a rich and diverse microbiota in individuals in the intervention group and by extension improving the overall health of these individuals.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
33
Inclusion Criteria
  • over the age of legal majority
  • delivery by planned C-section at term or vaginal delivery at term
  • registered at a social security service
Exclusion Criteria
  • HIV or other STD patients
  • immunocompromised patients
  • known streptococcus B carriers
  • known vaginal or perineal herpes infections
  • chronic disease patients (obesity, diabetes, IBD)
  • IMC before pregnancy > 30 kg/m²
  • antibiotic treatments one month before delivery
  • emergency C-section
  • Premature delivery (<37 amenorrhea weeks)
  • hospitalized for more than one week before delivery
  • known HVC infections
  • for the newborns: every diagnosed anomaly
  • patients who do not understand the research procedures or those that are institutionalized, or those unable to give informed consent
  • patients deprived of ther liberty by legal or administrative decisions
  • patients under an exclusion period from another study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intervention Groupperineal impregnated swab75 children born by planned C-section will be exposed to the perineal microbiota of their mothers through perineal impregnated swab.
Placebo Groupclean swab75 children born by planned C-section will be exposed to clean swab.
Primary Outcome Measures
NameTimeMethod
Diversity of the intestinal microbiota1 year

Intestinal microbiota diversity will be evluated through metagenomics.

Secondary Outcome Measures
NameTimeMethod
Health status1 year

Health status of the newborn will be evaluated through questionnaries.

Trial Locations

Locations (1)

Service de Gynécologie-Obstétrique, Groupe Hospitalier Pitié-Salpêtrière

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath